NCT03816319 - TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 12, 2025

Primary Completion Date

October 24, 2026

Study Completion Date

October 24, 2026

Conditions

Myelodysplastic Syndrome With Excess BlastsRecurrent Acute Myeloid LeukemiaRecurrent Myelodysplastic SyndromeRecurrent Myelodysplastic Syndrome/Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaRefractory Myelodysplastic SyndromeRefractory Myelodysplastic Syndrome/Acute Myeloid Leukemia

Interventions

PROCEDURE

Biospecimen Collection

Undergo urine and blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Echocardiography Test

Undergo ECHO

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

DRUG

UAE Inhibitor TAK-243

Given IV

Trial Locations (4)

23298

RECRUITING

VCU Massey Comprehensive Cancer Center, Richmond

33612

RECRUITING

Moffitt Cancer Center, Tampa

60611

RECRUITING

Northwestern University, Chicago

M5G 2M9

RECRUITING

University Health Network-Princess Margaret Hospital, Toronto

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH